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Abstract Clinical outcome of deep brain stimulation (DBS)
for obsessive-compulsive disorder (OCD) shows robust ef-
fects in terms of a mean Yale-Brown Obsessive-Compulsive
Scale (YBOCS) reduction of 47.7 % and a mean response
percentage (minimum 35 % YBOCS reduction) of 58.2 %.
It appears that most patients regain a normal quality of life
(QoL) after DBS. Reviewing the literature of the last 4 years,
we argue that the mechanisms of action of DBS are a combi-
nation of excitatory and inhibitory as well as local and distal
effects. Evidence from DBS animal models converges with
human DBS EEG and imaging findings, in that DBS may
be effective for OCD by reduction of hyperconnectivity
between frontal and striatal areas. This is achieved through
reduction of top-down-directed synchrony and reduction of
frontal low-frequency oscillations. DBS appears to coun-
teract striatal dysfunction through an increase in striatal
dopamine and through improvement of reward processing.
DBS affects anxiety levels through reduction of stress hor-
mones and improvement of fear extinction.
Keywords Deep brain stimulation . Obsessive-compulsive
disorder . Clinical outcome . Quality of life . Mechanisms of
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Introduction
Obsessive-compulsive disorder (OCD) affects 2 % of the gen-
eral population [1], causing severe functional impairment as a
result of anxiety, persistent intrusive thoughts (obsessions),
and behavioral inflexibility (compulsions). A small fraction
of these patients is unresponsive to standard treatment regimes
with cognitive behavioral therapy (CBT), multiple serotonin
reuptake inhibitors (SRIs), clomipramine, and addition of an-
tipsychotics [2]. For a subset of these treatment refractory
patients, ablative and neuromodulatory strategies are the last
options. Recently, deep brain stimulation (DBS) has been
approved as a reversible alternative for ablative stereotactic
neurosurgery or gamma-knife radiotherapy [3••]. DBS is a
chronic and invasive neuromodulatory technique with the
unique possibility of fine tuning its effects. DBS involves
stereotactic implantation of electrodes in deep brain struc-
tures [4], followed by a trial and error process of optimizing
parameter settings through telemetry in response to the pa-
tient’s feedback and clinical scores.
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This article critically reviews recent evidence on DBS for
OCD in order to bring the reader up to date with respect to (1)
clinical outcome in terms of Yale-Brown Obsessive-Compul-
sive Scale (YBOCS) and quality of life (QoL) and (2) recent
(January 2011–September 2014) clinical and preclinical evi-
dence on mechanisms of action of DBS. We will discuss side
effects elsewhere.We conducted an electronic literature search
covering journals with indexations in Embase, PsycINFO, and
PubMed as well as the Cochrane Library and the WHO trial
register, using the text words Bobsessive-compulsive
disorder^ and Bdeep brain stimulation.^ Because this combi-
nation yielded a limited amount of hits and using more spe-
cific search terms would introduce more selection bias, we
decided to manually select relevant studies. All primary clin-
ical outcome studies as well as case reports were included. All
clinical and preclinical studies on mechanisms of action from
2011 onward were included. We selectively included articles
before 2011 in so far as they helped to sketch the background
for our discussion of the recent studies.
Clinical Outcome
We identified 23 trials [5–27], and case reports that assessed
clinical outcome in terms of YBOCS scores of DBS for OCD
were included (see Table 1). It concerns 108 uniquely im-
planted patients, of which 49 were included in the studies of
Mallet et al. [22], Denys et al. [19], Goodman et al. [8], and
Huff et al. [18] that used a double-blind sham-controlled
crossover design. Five targets were used, including white mat-
ter tracts in the anterior limb of the internal capsule (ALIC) or
ventral capsule (VC) and the inferior thalamic peduncle (ITP)
and gray matter structures in the ventral striatum (VS), the
nucleus accumbens (NAc), and the subthalamic nucleus
(STN) [28]. Follow-up varied between 6 and 36 months.
Clinical outcome for all studies, together with each unique-
ly implanted patient weighted once, yields a mean YBOCS
reduction of 47.7 % and of 37.4 % for only the four random-
ized sham-controlled trials (RCTs). The mean response per-
centage (minimum 35 % YBOCS reduction [2]) is 58.2 % for
all studies and 43.8 % for the double-blind sham-controlled
studies, leaving out the study of Mallet et al. that used a lower
cutoff point of 25 % [22]. Placebo effects appear to be mini-
mal, as three out of four RCTs demonstrate significant differ-
ence between sham and stimulation conditions. VC/VS and
bilateral NAc targets, although more extensively studied,
show greater symptom improvement than the STN, and bilat-
eral NAc stimulation is more effective than right unilateral
NAc stimulation.
One presumedmeta-analysis [29] miscalculated effects and
had considerable inclusion bias [30]. We argue that differ-
ences in the designs of available studies currently obstruct
the conduction of a meta-analysis. Compatibility might be
increased through consistent use and publication of end points
and response rates. The same goes for standardization of pa-
rameter setting optimization of which the additional effect is
difficult to apprehend. One should also note that the high
prevalence of comorbid major depressive disorder (MDD)
may mediate effects on OCD. Lastly, more RCTs as well as
comparative studies between various targets, especially be-
tween VC/VS and STN, are necessary.
Quality of Life
Half of the DBS studies assessed Global Assessment of Func-
tioning (GAF) scores as a measure of QoL, which amounts to
a mean DBS-related GAF increase of 21.5 out of 100 points.
Interestingly, the study of Huff et al. [18] had a similar mean
GAF improvement despite the fact that only one of these
patients was a responder in terms of YBOCS, suggesting that
DBS may improve QoL independent of symptom improve-
ment. Correspondingly, the first clinical study on long-term
QoL effects of DBS for OCD found significant improvement
on the 26-item WHO QoL Scale-Brief Version (WHOQOL-
BREF), even in nonresponders in terms of YBOCS [31]. At
baseline, DBS-eligible OCD patients were impaired in all five
domains compared with age- and sex-matched healthy con-
trols. The physical and psychological domains, which were
most severely impaired at baseline, improved with 23 and
27 %, respectively, at 8 months post-surgery, and with a total
of 39.5 % at 3–5 years post-surgery compared to baseline.
Improvement in physical and environmental domains corre-
lated with symptom improvement on the YBOCS and with
improvement of depression and anxiety on the Hamilton
Rating Scale for Depression (HAM-D) and Hamilton Rating
Scale for Anxiety (HAM-A). The environmental domain
(financial, housing, mobility) also improved significantly
with 16 %. Only the social domain did not significantly
improve, and this was especially due to patients with long
illness durations. The overall score improved with 90 %,
approaching the normal range, indicating that patients might
in fact regain a normal standard of QoL. It appears, however,
that DBS is a chronic treatment and that improvements on
QoL disappear after acute DBS cessation. This also causes a
relapse of obsessions and compulsions and a rebound of
anxiety and depression which exceeds pre-surgery levels
with approximately 40 % [32].
Mechanisms of Action
The mechanisms of action of DBS that mediate the clinical
effects discussed above were initially understood as equiva-
lent to the lesion effects of ablative surgery [6]. DBS was
thought to locally inhibit excessive pathological activity. In
recent years, it has been acknowledged that facilitation of
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informational signals is crucial. Tellingly, there has been a
shift in focus from local effects towards connectivity on the
system level [33]. We review clinical and preclinical evidence
published in the last 4 years and show that the mechanisms of
action of DBS are a combination of excitatory and inhibitory
as well as local and distal effects.
Behavioral Studies
Using selective SRI (SSRI)-validated animal models [34, 35],
pathognomonic features of OCD, including cognitive and be-
havioral inflexibility, attenuated reward processing, and anxiety
levels have been assessed in relation to DBS. High-frequency
(presumably inhibitory) DBS of the lateral orbitofrontal cortex
(OFC) resulted in behavioral inflexibility during a reversal
learning task [36], suggesting that local high-frequency stimu-
lation disrupted OFC control over striatal areas, thereby induc-
ing perseverative behaviors. Furthermore, reduced compulsive
lever pressing was found with high but not with low-frequency
stimulation of the rat’s equivalent of the globus pallidus region,
which may be explained by activation of passing corticofugal
fibers of the internal capsule [37]. Besides these effects on
compulsive behaviors, DBS of several other subcortical areas
affected unconditioned or conditioned anxiety. Caudate nucleus
(CN)-DBS reduced both forms of anxiety, VS-DBS reduced
only conditioned anxiety, while NAc and bed nucleus of the
stria terminalis (BNST)-DBS did not have any effect on anxiety
[38]. Adding to this, VC/VS-DBS during extinction training
reduced fear expression and increased fear extinction, which
was associated with an increase in OFC, medial prefrontal cor-
tex (mPFC), and amygdala of activity-associated plasticity
markers, such as pERK, c-Fos, and BDNF [39•, 40•]. These
findings confirm the idea that DBS and CBT, of which extinc-
tion is a central element, act as two complementary treatments.
Indeed, a recent open-label and uncontrolled clinical DBS trial
revealed that the mean YBOCS score and the mean response
percentage (minimum 35%YBOCS reduction) improved from
25 to 42 % and from 50 to 72 %, respectively, after augmenta-
tion with 24 weeks of CBT [41]. DBS might reduce anxiety
through modulation of the stress hormones, shown by an in-
crease in plasma glucose levels in an animal study [42] and
YBOCS-correlated normalization of hypercortisolism in
humans [43]. In sum, DBS animal models suggest that the
stimulation of OFC striatal fibers improves a compulsive be-
havior, with more ventral stimulation being related to reduced
fear conditioning and improved fear extinction as well.
Neurotransmitter Studies
OCD phenomenology, and in particular aberrant reward pro-
cessing, has been related to dysfunction of dopaminergic neu-
rotransmission [44]. A SPECT study in humans with NAc-
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potential, which was correlated with long-term clinical im-
provement and increased plasma levels of homovanillic acid,
a dopamine metabolite [45]. This indicates DBS-induced in-
crease in striatal dopamine, which might imply that previous
findings of increased dopamine transporter (DAT) availability
and decreased dopamine D1, a D2/3 receptor density in the
striatum of OCD patients [46, 47], did not so much indicate
downregulation but intrinsic compensatory dopamine release,
which is enhanced by DBS. These effects of DBS on dopamine
levels might be indirect. A robust finding is that serotonine
reuptake inhibitors (SRIs) are effective in reducing symptoms
[48] and influence striatal dopamine levels. Possibly, the sero-
tonergic deficits that are typically found in OCD patients, in-
cluding decreased SERTavailability in thalamic and brain stem
regions and increased cortical postsynaptic 5-HT2A receptor
availability [46, 47], mediate striatal dopaminergic dysfunction.
Recent microdialysis studies in healthy rats with NAc-DBS
show a rapid increase of both dopamine and serotonin re-
lease in frontal cortex areas (OFC andmPFC) [49], but not in
the striatal area (NAc) where the stimulating electrode was
located [50]. From local recordings in acute rat brain slices,
we know that high-frequency stimulation (140 Hz) of the
NAc significantly suppresses spontaneous local neuronal fir-
ing. This suppression could be selectively reversed through
the application of GABAB and non-GABAA antagonists [51].
Possibly, DBS activates GABA-ergic inhibitory interneurons.
Imaging Studies
Structural brain imaging of OCD patients reveals increased
gray matter volume of striatal areas (CN and putamen) and
decreased volume of frontal cortical areas (anterior cingulate
(ACC) and OFC) [52]. Functional imaging indicates hyperac-
tivity in both striatal and frontal areas (CN and OFC) in resting
state and during symptom provocation [53]. Taken together,
OCD pathophysiology implies hyperconnectivity between
frontal and striatal areas. This long-standing hypothesis was
confirmed by DBS-induced normalization of excessive cou-
pling between frontal cortex and NAc in a recent fMRI study
in OCD patients. This was paralleled by a normalization of
decreased NAc activity [54•]. Recent studies on clinical
cohorts of OCD patients treated with STN-DBS [55] and
NAc-DBS [54•] show a similar YBOCS-correlated decrease
of activity in frontal and striatal areas as had been observed
with treatment with SSRIs or CBT [56]. Hyperconnectivity of
brain areas in OCD pathophysiology likely includes hyperactiv-
ity or hypoactivity in the limbic system, thalamus, and parietal
cortex, too [57, 58]. Recent PET findings of DBS-eligible OCD
patients include increased resting state metabolism in ACC, oc-
cipital cortex, and posterior cerebellum. Several months of VC/
VS-DBS resulted in decreased metabolism in anterior cingulate
and prefrontal and orbitofrontal cortices although uncorrelated
to YBOCS improvement [59]. Preclinical findings from NAc-
DBS in healthy pigs include activation of prefrontal, insular,
cingulate, and parahippocampal regions [60]. Together with
the above-discussed evidence from behavioral and neurotrans-
mitter studies, these functional imaging findings converge with
the hypothesis that DBS improves OCD by restoring
corticostriatal function, possibly in a top-down direction through
activation of distant neural assemblies [61, 62].
Electrophysiological Studies
In line with the aforementioned imaging findings, neuronal
populations in the striatum of OCD patients show aberrant
discharge patterns. Studies on local recordings in the STN
through unconnected DBS electrodes in OCD found increased
burst firing in STN neurons in resting state. During symptom
provocation, synchrony in the discharge pattern of STN neu-
rons is significantly increased [64]. Patients with lower
interburst intervals and higher intraburst frequency had the
best YBOCS outcome [65]. Moreover, OCD symptom sever-
ity could be predicted by STN discharge patterns. The most
severe cases were related to a higher intraburst frequency and
more low-frequency oscillations where present [65]. The
functional role of this aberrant bursting pattern in OCD, for
instance its relation to dopamine levels, remains unclear. To
our knowledge, no studies combined in vivo local recordings
with active STN-DBS or did local recordings in patients after
successful DBS treatment. NAc activity has predictive capacity
on a short timescale and has been studied under active stimu-
lation. Intraoperative local recordings in OCD and MDD pa-
tients during a gambling task revealed that seconds before their
decision is physically manifested, NAc activity already signif-
icantly predicts whether subjects will bet high or low. If the
result is unexpected, NAc activity successively potentiates
when positive and attenuates when negative, which might im-
plicate that the NAc, together with the midbrain dopaminergic
system, facilitates reinforcement learning [63]. Although imag-
ing studies point that DBS directly modulates this activity re-
mains unclear, as NAc-DBS in acute rat brain slices had no
effect on the discharge pattern or synchrony of local NAc neu-
rons [51], and with NAc-DBS, the bursting pattern of dopami-
nergic neurons in nigrostriatal and mesolimbic areas in healthy
anesthetized rats appeared to be unaltered [66]. One study con-
nected direct local recordings of NAc neurons with surface
EEG of the frontal cortex and found top-down-directed syn-
chrony from the frontal cortex to NAc in low-frequency bands
during reward anticipation in OCD patients [67]. Moreover,
low-frequency oscillations are reduced by NAc-DBS, as was
shown by EEG recordings both during resting state [68] and
symptom provocation [54•]. These strands of evidence support
the hypothesis that the hyperconnectivity of frontal and striatal
brain areas, observed with functional imaging, is mediated by
low-frequency oscillations, which are typically associated with
long distance communication in the brain [69].
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Conclusion
Clinical outcome of deep brain stimulation (DBS) for obsessive-
compulsive disorder (OCD) shows robust effects in terms of a
mean Yale-Brown Obsessive-Compulsive Scale (YBOCS) re-
duction of 47.7 % and a mean response percentage (minimum
35 % YBOCS reduction) of 58.2 %. Additionally, it appears
that most patients regain a normal quality of life after DBS.
The interpretation of these findings is limited by variations in
study designs with respect to the use of a blinded control
condition, brain targets, end points, comorbidity, and parame-
ter setting optimization.
Considering the current evidence, it is most likely that the
mechanisms of action of DBS are a combination of excitatory
and inhibitory as well as local and distal effects. Evidence
from DBS animal models converges with human DBS EEG
and imaging findings, in that DBS may be effective for OCD
by reduction of frontostriatal hyperconnectivity, which is like-
ly achieved through reduction of top-down-directed synchro-
ny and reduction of frontal low-frequency oscillations. DBS
appears to counteract striatal dysfunction through an increase
in striatal dopamine and through improvement of reward pro-
cessing. DBS affects anxiety levels through reduction of stress
hormones and improvement of fear extinction. The latter re-
lates to epigenetic changes in frontal cortical areas. Further
research needs to elucidate how this relates to DBS-induced
increase in frontal dopamine and serotonin levels. The ob-
served distal effects with NAc-DBS, in terms of a decrease
in prefrontal cortex metabolism, are also observed in DBS of
the STN, which is also connected to frontal cortical areas. The
functional role of aberrant bursting patterns of STN neurons in
OCD, for instance its relation to dopamine levels, remains
unclear. Future studies could combine in vivo local recordings
with active STN-DBS or perform local recordings in patients
after successful DBS treatment.
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